metopimazine (NG101) / Neurogastrx - LARVOL DELTA

A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a GLP-1 Agonist (clinicaltrials.gov) - P2 | N=120 | Completed | Sponsor: Neurogastrx, Inc. | Active, not recruiting ➔ Completed

Adverse events • Trial completion • Genetic Disorders • Obesity

A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a GLP-1 Agonist (clinicaltrials.gov) - P2 | N=120 | Active, not recruiting | Sponsor: Neurogastrx, Inc. | Recruiting ➔ Active, not recruiting

Adverse events • Enrollment closed • Genetic Disorders • Obesity

A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a GLP-1 Agonist (clinicaltrials.gov) - P2 | N=150 | Recruiting | Sponsor: Neurogastrx, Inc.

New P2 trial • Genetic Disorders • Obesity

A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis (clinicaltrials.gov) - P2 | N=162 | Completed | Sponsor: Neurogastrx, Inc. | Active, not recruiting ➔ Completed

Trial completion • Gastrointestinal Disorder

A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis (clinicaltrials.gov) - P2 | N=140 | Active, not recruiting | Sponsor: Neurogastrx, Inc. | Recruiting ➔ Active, not recruiting | N=280 ➔ 140

Enrollment change • Enrollment closed • Gastrointestinal Disorder

A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis (clinicaltrials.gov) - P2 | N=280 | Recruiting | Sponsor: Neurogastrx, Inc. | Trial completion date: Jun 2022 ➔ Apr 2023 | Trial primary completion date: Mar 2022 ➔ Mar 2023

Trial completion date • Trial primary completion date • Gastrointestinal Disorder

Metopimazine is primarily metabolized by a liver amidase in humans. (PubMed, Pharmacol Res Perspect) - "Analysis of plasma samples from subjects dosed 60 mg of MPZ verified that these oxidative pathways are very minor and that CYP enzyme involvement was negligible compared to microsomal amidase/hydrolase in overall MPZ metabolism in humans. The metabolism by liver amidase, an enzyme family not well defined in small molecule drug metabolism, with minimal metabolism by CYPs, differentiates this drug from current D2 antagonists used or in development for the treatment of GP."

Journal • Gastrointestinal Disorder • CYP3A4 • DRD2

A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis (clinicaltrials.gov) - P2; N=280; Recruiting; Sponsor: Neurogastrx, Inc.; Trial completion date: Jun 2021 ➔ Jun 2022; Trial primary completion date: Mar 2021 ➔ Mar 2022

Clinical • Trial completion date • Trial primary completion date • Gastrointestinal Disorder

A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis (clinicaltrials.gov) - P2; N=280; Recruiting; Sponsor: Neurogastrx, Inc.; Not yet recruiting ➔ Recruiting; Initiation date: Mar 2020 ➔ Aug 2020

Clinical • Enrollment open • Trial initiation date • Gastrointestinal Disorder

A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis (clinicaltrials.gov) - P2; N=280; Not yet recruiting; Sponsor: Neurogastrx, Inc.

Clinical • New P2 trial